Sionna Therapeutics (SION) Equity Ratio (2024 - 2026)
Quarterly results put Equity Ratio at 0.94 for Q1 2026, down 0.71% from a year ago — trailing twelve months through Mar 2026 was 0.94 (down 0.71% YoY), and the annual figure for FY2025 was 0.94, up 206.81%.
Sionna Therapeutics has reported Equity Ratio over the past 3 years, most recently at 0.94 for Q1 2026.
- Equity Ratio reached 0.94 in Q1 2026 per SION's latest filing, roughly flat from 0.94 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.96 in Q2 2025 and bottomed at 0.88 in Q4 2024.
- Median Equity Ratio over the past 3 years was 0.95 (2025), compared with a mean of 0.64.
- The largest annual shift saw Equity Ratio skyrocketed 206.81% in 2025 before it decreased 0.71% in 2026.
- Over 3 years, Equity Ratio stood at 0.88 in 2024, then surged by 206.81% to 0.94 in 2025, then rose by 0.37% to 0.94 in 2026.
- Business Quant data shows Equity Ratio for SION at 0.94 in Q1 2026, 0.94 in Q4 2025, and 0.95 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 0.04 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 0.42 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 0.73 |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 0.77 |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 0.21 |
| 10 | Sionna Therapeutics | 1.87 Bn | 1.87 Bn | - | 0.94 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.94 |
| Dec 31, 2025 | 0.94 |
| Sep 30, 2025 | 0.95 |
| Jun 30, 2025 | 0.96 |
| Mar 31, 2025 | 0.95 |
| Dec 31, 2024 | -0.88 |